Literature DB >> 2179082

[D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness].

D Lindenberg1, H Pitule-Schödel.   

Abstract

In a placebo-controlled double blind clinical trial, 38 out-patients with anxiety associated with neurotic or psychosomatic disturbances were treated with D,L-Kavain (Neuronika) or Oxazepam. The anxiolytic effectiveness of the two preparations was judged by means of the Anxiety Status Inventory (ASI) and the Self-Rating Anxiety Scale (SAS) of Zung. The substances proved to be equivalent in the nature and potency of anxiolytic action. No adverse drug reactions occurred.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179082

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  4 in total

1.  Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced O6-Methylguanine and Lung Tumor in A/J Mice.

Authors:  Manohar Puppala; Sreekanth C Narayanapillai; Pablo Leitzman; Haifeng Sun; Pramod Upadhyaya; M Gerard O'Sullivan; Stephen S Hecht; Chengguo Xing
Journal:  J Med Chem       Date:  2017-09-13       Impact factor: 7.446

Review 2.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  A re-evaluation of kava (Piper methysticum).

Authors:  E Ernst
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

4.  Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism.

Authors:  Han Chow Chua; Emilie T H Christensen; Kirsten Hoestgaard-Jensen; Leonny Y Hartiadi; Iqbal Ramzan; Anders A Jensen; Nathan L Absalom; Mary Chebib
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.